title: Isotretinoin for acne and rosacea.
abstract: Isotretinoin is a revolutionary medicine for the treatment of acne vulgaris, with new studies showing evidence of excellent clinical outcomes in treating rosacea. After 30 years of clinical experience, new insights are being gained into dosing strategies, recurrence prevention, and dose-related side effects. Previous controversial associations with inflammatory bowel diseases and mood disorders have hampered the use of this medication in some clinical situations, with new evidence disproving these claims. The teratogenicity of this medication mandates iPLEDGE compliance with government regulations. Clinicians should be knowledgeable about this medication including its side effects, teratogenicity, and its controversies in order to adequately counsel patients, dissuade fears, and obtain the best clinical outcome when treating acne and rosacea.
authors.affiliation: Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA.
authors.forename: Kendra D
authors.initials: KD
authors.lastname: Watson
authors.affiliation: Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA.
authors.forename: Rachel Y
authors.initials: RY
authors.lastname: Miest
authors.affiliation: Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA.|Department of Pediatrics, Mayo Clinic, Rochester, Minnesota, USA. Tollefson.Megha@mayo.edu.
authors.forename: Megha M
authors.initials: MM
authors.lastname: Tollefson
mesh_terms: D000152:Acne Vulgaris / Q000188:drug therapy*; D003879:Dermatologic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D019317:Evidence-Based Medicine; D017408:Guidelines as Topic; D006801:Humans; D015474:Isotretinoin / Q000008:administration & dosage* / Q000009:adverse effects; D012008:Recurrence; D018570:Risk Assessment; D012307:Risk Factors; D012393:Rosacea / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D003879:Dermatologic Agents; D015474:Isotretinoin